placebo + enzalutamide

The combination of placebo + enzalutamide refers to the control arm of the TALAPRO-2 Phase 3 clinical trial, which evaluated the efficacy of adding the PARP inhibitor talazoparib to standard-of-care enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide, marketed as Xtandi, is a small molecule androgen receptor signaling inhibitor. It functions by blocking the binding of androgens to the androgen receptor, inhibiting the translocation of the receptor into the cell nucleus, and preventing the receptor from binding to DNA. This multi-step inhibition effectively shuts down the androgen signaling pathway that fuels the growth of prostate cancer cells. In the TALAPRO-2 study, this combination served as the comparator to establish a baseline for radiographic progression-free survival (rPFS) against which the talazoparib combination was measured.

Brand names

Xtandi

Other names

enzalutamide plus placebo